Bios Partners
Venture capitalFort Worth · Seed–Growth · 15 people tracked
Also known as BIOS CAPITAL MANAGEMENT, LP · STEELHEAD CAPITAL MANAGEMENT, LLC
Investment thesis
Bios Partners argues that scientific talent is distributed evenly across the country while venture capital concentrates on the coasts, particularly Silicon Valley and the Northeastern US. The firm seeks to disrupt this 'geographic favoritism' by investing in scientifically compelling opportunities in the Central US that are typically overlooked and undervalued. Its approach centers on company cultivation and is driven by science, drawing on a team with combined experience across hedge funds, private equity, clinical drug development, and public pharma/biotech analysis.
Source: firm website, verified Aug 11, 2026.
Team · 15 people
from the firm's website & public directories
What they invest in
from 9 of 9 portfolio companiesBiotech ×8Healthtech ×3Medical Devices ×2Hardware ×1
HQs:United States×9
Investments · 9 tracked
founders shown can be your intro pathBy year:2025 · 12022 · 22021 · 22020 · 12018 · 12015 · 18 dated
Clinical-stage therapeutics company focusing on high-impact cancers and inflammatory diseases.
BiotechFort Worth, US
Daniel Schmitt(Executive Officer, Director)Andrew Mazar(Executive Officer)Paul Lytle(Executive Officer)Leslie Wayne Kreis, Jr.(Director, Promoter)
BoardTodd Thomson(Director)Roger Sawhney(Director)
Board seatAaron G.L. FletcherLeslie W. Kreis, Jr.· per SEC Form D · $5M raise · filed Mar 2024
BiotechFarmington, US
Azim Munivar(Executive Officer, Director, Promoter)
Board seatStella RobertsonTravis Whitfill· per SEC Form D · $4.5M raise · filed Oct 2022
BiotechBoston, US
Daniel Baker(Executive Officer)Colin Sandercock(Executive Officer)Dominic Borie(Executive Officer)Sumita Ray(Executive Officer)Daniel Camardo(Director)Viola Meehan(Director)
Board seatAaron G.L. Fletcher· per SEC Form D · $30M raise · filed Nov 2022
Trefoil Therapeutics develops ophthalmologic drugs, with a team focused on drug development and commercialization in the eye-care field.
BiotechHealthtechSan Diego, US
Ralph Bradshaw(Director)Schalon Newton(Executive Officer)David Eveleth(Executive Officer, Director)
BoardChristy Shaffer(Director)
Board seatStella Robertson· per SEC Form D
ONL Therapeutics is a clinical-stage biopharmaceutical company developing neuroprotective treatments for retinal diseases including retinal detachment, geographic atrophy, and glaucoma.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Executive Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)Loic Couraud(Director)William Brinkerhoff(Director)Mark Hooper(Director)
410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation.
HardwareHealthtechMedical DevicesDurham, US
Mark Donald Piehl(Executive Officer, Director)KYLE CHENET(Executive Officer, Director)Mike Liddell(Manager)Lukas Miller Roush(Manager)
BoardJEFF TERRELL(Director)STANLEY D. LYNALL(Director)
Board seatTravis Whitfill· per SEC Form D · $4M raise · filed Aug 2018
BiotechHummelstown, US
Stephen C. Rocamboli(Executive Officer, Director)Rifat Pamukcu(Director)Robert Towarnicki(Executive Officer, Director)Roger Sawhney(Director)
BoardJohn Fucci(Director)
Board seatTim Van Treuren· per SEC Form D · $42.1M raise · filed Jan 2024
BiotechAustin, US
Aaron Fletcher(Director)Joseph Woelkers(Director)Steven Idell(Director)Robert Mills(Director)James Brian Windsor(President and CEO)
Board seatAaron G.L. Fletcher· per SEC Form D · $15M raise · filed Apr 2022
Preclinical biotech developing first-in-class treatments for serious neurodegenerative disorders such as stroke, using its engineered perlecan domain V.
BiotechHouston, US
Chris Garabedian(Director)William Schwieterman(Executive Officer, Director)Fred Callori(Director)
BoardAmanda De La Garza(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioActuate TherapeuticsNASDAQ: ACTUAzitraNYSE: AZTRCue BiopharmaNASDAQ: CUE
Portfolio news
latest coverage across their companiesCue Biopharma · tipranks.com · Aug 3, 2026
Frequently asked questions
- What stage does Bios Partners invest at?
- Bios Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does Bios Partners focus on?
- Bios Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is Bios Partners located?
- Bios Partners is headquartered in Fort Worth, US.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.